September 23, 2017 |
UCLA Researchers Reveal Early Imaging Leads to Better Outcomes for Alzheimer's Patients
September 24, 2013  | 

Los Angeles, CA - Patients suffering from early symptoms of Alzheimer’s disease who were diagnosed sooner than usual using a brain imaging test received Alzheimer-specific medications earlier than those who did not have the brain imaging results available to their doctors or themselves. These patients also had significantly better clinical outcomes during the subsequent years they were clinically monitored, UCLA researchers have found for the first time. 

The Metabolic Cerebral Imaging in Incipient Dementia study is an ongoing national clinical trial sponsored by the Centers for Medicare and Medicaid Services (CMS). These interim data found that patients whose doctors gleaned information from a brain PET scan performed with the tracer FDG did better over two years than those whose doctors were randomized to not have access to the scan information. 

“During the subsequent two years after their PET scans, these patients had superior executive function, better memory abilities and greater preservation of overall cognitive function, providing the first direct evidence that patients whose early Alzheimer’s disease is revealed by FDG-PET will do better than patients with the same condition, but with their brain metabolism pattern remaining unknown to their doctors and themselves,” said study principal investigator Daniel Silverman, a UCLA professor of molecular and medical pharmacology. Continue>

Page | 1 2 3 4
Suggested Articles